Le Lézard
Classified in: Health, Science and technology, Business
Subject: ERN

Neogen reports third quarter results


LANSING, Mich., March 22, 2018 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that its revenues for the third quarter of its 2018 fiscal year, which ended Feb. 28, increased 8% to $95,892,000, from the previous year's third quarter revenues of $88,385,000. Current year-to-date revenues were $292,965,000, up 12% compared to $262,747,000 for the same period a year ago.

Third quarter net income was $16,586,000, an increase of 61% compared to the prior year's $10,287,000. Adjusted for a 4-for-3 stock split effective Dec. 29, 2017, earnings per share in the current quarter were $0.32, compared to $0.20 a year ago. In the current quarter, Neogen benefitted from corporate tax rate reform enacted in December 2017, which resulted in an effective tax rate of 4% for the quarter, compared to 34% in the prior year. Current year-to-date net income was $45,600,000, or $0.88 per share after being adjusted for the split, compared to $31,320,000, or an adjusted $0.61 per share, for the same period a year ago.

"We are pleased to report solid third quarter performance, in which we continued to integrate recent complementary acquisitions while keeping our focus on sales growth," said James Herbert, Neogen's executive chairman. "In addition, during the quarter, Neogen benefitted from Washington's long-discussed reduction of the corporate tax rate. These tax savings will allow us to continue to aggressively pursue our proven growth strategies."

The third quarter was the 104th of the past 109 quarters that Neogen reported revenue increases as compared with the previous year ? a record spanning over 27 years.

"We were generally pleased with our performance in the quarter, especially considering that we were facing a difficult comparison with last year's third quarter. The prior year's quarter featured strong sales of mycotoxin test kits due to an outbreak of DON in crops in the U.S. and Europe, and sales of a disinfectant product line that we no longer offer," said John Adent, Neogen's president and chief executive officer. "The current quarter had revenue increases in core product lines across our food and animal market segments, including strong growth in our global agricultural genomics services."

Neogen's gross margin was 47.5% of sales in the third quarter of the current year, compared to 46.3% in the same quarter of the prior fiscal year, positively impacted by cost improvements in its genomics service business and favorable product mix in its animal safety product lines. Expressed as a percentage of sales, operating income was 16.6% for the current quarter, compared to 16.2% in the third quarter of the 2017 fiscal year.

"We were able to increase our operating income 11% in the current quarter on 8% growth in revenues," said Steve Quinlan, Neogen's chief financial officer. "We continue to invest in infrastructure to position the company to capitalize on our growth opportunities."

Revenues for the company's Food Safety segment increased 11% during the third quarter compared to the prior year quarter. Sales of Neogen's rapid diagnostics to detect food allergens, including gluten, milk, soy and peanuts, increased 14% in the current quarter. Sales of the company's general sanitation products increased 18% in the third quarter of the 2018 fiscal year, compared to the prior year quarter, and sales of its foodborne pathogen detection tests increased 22% ? including a 43% increase in sales of tests to detect Listeria

Included in the Food Safety segment's current third quarter results was a 29% increase in sales of test kits to detect drug residues in milk. In February, Neogen launched BetaStar® Advanced tests for beta-lactam and tetracycline antibiotics in milk. The new tests were developed for the U.S. market, and designed to be performed with Neogen's new Raptor® testing platform. Raptor allows testers to easily perform up to nine tests at once. The Raptor platform is also designed to work with other Neogen tests. 

In the current quarter, revenues from international sources increased to 39% of total revenues, compared to 36% in the prior year quarter. Overall, international sales for the quarter increased 17% over the prior year, aided by acquisitions. For the current quarter, Neogen Europe's revenues rose 15% in U.S. dollars, aided by growth in genomics services, Lab M sales rose 20% as its products have been increasingly integrated into the company's distribution channels, Mexico-based Neogen Latinoamerica's sales increased 19% and Neogen China's revenues increased 28%, each on broad-based increases across its product offerings.

Neogen's Animal Safety segment reported a revenue increase for the third quarter of 6%, led by growth in genomics business, an 11% increase in its rodent control product lines, a 19% increase in sales of drug detection products, a 14% increase in sales of detectable needles, and a 26% increase in sales of its animal care line of products, which includes animal wound care products, vitamin injectables, and supplements. These gains overcame lower sales of cleaners and disinfectants, which resulted from the termination of a distribution agreement in the prior year. 

Neogen's worldwide animal genomics business recorded a broad-based increase of 25% in the third quarter of fiscal 2018 compared to the prior year. This increase was aided in part by the September 2017 acquisition of the Neogen Australasia genomics laboratory in Australia, but was driven more significantly by increases in revenues from genomic testing of beef and dairy cattle, swine, poultry, and companion animals at our previously existing locations.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division is a leader in worldwide biosecurity products, animal genomics testing, and the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals and veterinary instruments.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.

CONTACT:    Steve Quinlan, Vice President & CFO
                       Neogen Corporation, 517/372-9200

 

NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA

(In thousands, except for per share and percentages)



Quarter ended Feb. 28


Nine months ended Feb. 28



2018



2017



2018



2017

Revenue

Food Safety

$

47,645


$

42,949


$

143,940


$

123,067

Animal Safety


48,247



45,436



149,025



139,680

Total revenue


95,892



88,385



292,965



262,747

Cost of sales


50,371



47,505



152,302



137,797

Gross margin


45,521



40,880



140,663



124,950

Operating expenses

Sales & marketing


17,492



15,340



52,331



45,824

Administrative


9,280



8,548



29,096



25,094

Research & development


2,836



2,641



8,901



8,087

Total operating expenses


29,608



26,529



90,328



79,005

Operating income


15,913



14,351



50,335



45,945

Other income


1,368



1,376



3,235



1,788

Income before tax


17,281



15,727



53,570



47,733

Income tax


700



5,350



7,900



16,250

Net income

$

16,581


$

10,377


$

45,670


$

31,483

Net (income) attributable
   to non-controlling interest


 

5



 

(90)



 

(70)



 

(163)

Net income attributable to Neogen Corp

$

16,586


$

10,287


$

45,600


$

31,320

Net income attributable to Neogen Corp












per diluted share (1)

$

0.32


$

0.20


$

0.88


$

0.61


Other information:

Shares to calculate per share (1)


52,237



51,379



52,014



51,161

Depreciation & amortization

$

4,411


$

3,653


$

12,681


$

10,691

Interest income


524



271



1,322



690

Gross margin (% of sales)


47.5%



46.3%



48.0%



47.6%

Operating income (% of sales)


16.6%



16.2%



17.2%



17.5%

Revenue increase vs. FY 2017


8.5%






11.5%




Net income increase vs. FY 2017


61.2%






45.6%





(1) Reflects effect of Dec. 29, 2017, 4-for-3 stock split

 

NEOGEN CORPORATION SUMMARIZED CONSOLIDATED

BALANCE SHEET DATA

(In thousands)



Feb. 28



May 31



2018



2017



(Unaudited)



(Audited)

Assets






Current assets






Cash & investments

$

192,155


$

143,635

Accounts receivable


73,209



68,576

Inventory


77,506



73,144

Other current assets


9,334



7,606

Total current assets


352,204



292,961

Property & equipment, net


72,514



61,748

Goodwill & other assets


170,883



173,700

Total assets

$

595,601


$

528,409







Liabilities & Equity






Current liabilities

$

37,293


$

36,002

Long-term liabilities


16,373



20,650

Equity: Shares outstanding

51,583 in Feb. & 50,932 in May (1)


 

541,935



 

471,757

Total liabilities & equity

$

595,601


$

528,409


(1) Reflects effect of Dec. 29, 2017, 4-for-3 stock split

 

SOURCE Neogen Corporation


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: